Treatment of High-grade Gliomas Using Hypofractionated Radiation Therapy -a Phase I Clinical Trial
Status:
Completed
Trial end date:
2016-12-03
Target enrollment:
Participant gender:
Summary
Postoperative conventional radiation at 60 Gy/30f is currently still considered the standard
radiotherapy mode for high-grade gliomas; however, the efficacy is still unsatisfactory.
Studies in recent years have shown that hypofractionated simultaneous integrated
boost-intensity modulated radiation therapy (SIB-IMRT) has certain survival benefits over
other fractionation methods; but, the best hypofractionation mode and its efficacy have not
been confirmed. The purpose of this study is to investigate the maximum tolerated dose (MTD)
of hypofractionated SIB-IMRT with stepwise escalating of doses combined with temozolomide
(TMZ) for the treatment of malignant gliomas.